In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
The pace of privatisation of the Indian healthcare segment is expected to be the fastest in the coming years.
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
Data from the Central Information Commission, the apex body that hears complaints regarding denial of information under RTI, shows that corporate houses are increasingly using RTI to extract information from public authorities.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Pfizer's blockbuster drug Viagra (sildenafil citrate), hitherto approved for use in treatment of erectile dysfunction, may soon acquire a new identity as a "life saving drug" in treating pulmonary arterial hypertension in children.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
Fortis Healthcare, promoted by the Singh family of Ranbaxy, plans to expand its network to 40 hospitals within three years by either acquiring new facilities or setting up greenfield projects
Beer is gaining more popularity in some of the non-traditional beer markets in North India like Rajasthan, Punjab, Delhi and Uttar Pradesh.
Australia has joined the UK, USA and Canada in warning its citizens against using unapproved traditional medicines from India and China.
Amgen, the world's largest biotechnology company, has entered India by opening a wholly owned subsidiary Amgen Technology in Mumbai.
Hetero is the only Indian partner of multinational drug major Roche Scientific for the manufacture and supply of the latter's patented drug, Tamilflu in developing countries.
Merck is all set to introduce three of its money-spinning drugs - Cosopt, Invanz and Pneuvax in India.
Pharmaceutical companies which increase prices of their medicines beyond 10 per cent in a year will face regulatory action.
Mumbai-based Advanced Enzyme Technologies Ltd, the largest manufacturer of enzymes in the country, will invest Rs 115 crore to set up three biotech production facilities.
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances